KAMADA Business Summary

Kamada Ltd. (KMDA) is a vertically integrated biopharmaceutical leader specializing in the development, manufacture, and commercialization of specialty plasma-derived protein therapeutics for rare and serious conditions. The company generates revenue through two primary segments: Proprietary Products, which includes a portfolio of FDA-approved therapies such as GLASSIA for Alpha-1 Antitrypsin Deficiency and KEDRAB for rabies prophylaxis, and a Distribution segment that markets third-party biopharmaceuticals and biosimilars in Israel and the MENA region. Kamada further diversifies its income through its U.S.-based plasma collection subsidiary, Kamada Plasma, which supports vertical integration and generates high-margin sales of normal source plasma. In a market dominated by global giants like CSL Behring, Grifols, and Takeda Pharmaceutical, Kamada maintains a competitive niche as a high-efficiency specialist in orphan diseases and hyperimmune globulins, leveraging proprietary protein purification technology to maintain double-digit revenue growth and robust EBITDA margins. Originally founded in 1990 by David Tsur and Ralph Hahn in collaboration with Kibbutz Beit Kama, the company is currently led by Chief Executive Officer Amir London, who brings over 20 years of experience from roles at Fidelis Diagnostics and Promedico. The executive team includes Chief Financial Officer Chaime Orlev, formerly of Bioblast Pharma and Chiasma, and Chief Operating Officer Eran Nir, who previously managed major production facilities for Teva Pharmaceutical. Technical innovation is overseen by VP of Research and Development Michal Ayalon. The company is strategically anchored by its controlling shareholder, FIMI Opportunity Funds, which holds approximately a 38% stake. The board is chaired by Lilach Asher Topilsky, a Senior Partner at FIMI, while co-founder David Tsur continues to provide strategic guidance as Deputy Chairman.